vs

Side-by-side financial comparison of Aquestive Therapeutics, Inc. (AQST) and KKR Real Estate Finance Trust Inc. (KREF). Click either name above to swap in a different company.

KKR Real Estate Finance Trust Inc. is the larger business by last-quarter revenue ($25.8M vs $13.0M, roughly 2.0× Aquestive Therapeutics, Inc.). KKR Real Estate Finance Trust Inc. runs the higher net margin — -101.7% vs -244.8%, a 143.0% gap on every dollar of revenue. On growth, Aquestive Therapeutics, Inc. posted the faster year-over-year revenue change (9.7% vs -26.6%). Over the past eight quarters, Aquestive Therapeutics, Inc.'s revenue compounded faster (3.9% CAGR vs -18.8%).

Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.

KKR Real Estate Finance Trust Inc. is a specialized real estate finance firm sponsored by global investment firm KKR. It primarily originates, acquires, and manages a portfolio of senior secured commercial real estate loans, mostly backed by high-quality institutional commercial properties across the United States, delivering stable risk-adjusted returns to investors via interest income from its diversified assets.

AQST vs KREF — Head-to-Head

Bigger by revenue
KREF
KREF
2.0× larger
KREF
$25.8M
$13.0M
AQST
Growing faster (revenue YoY)
AQST
AQST
+36.3% gap
AQST
9.7%
-26.6%
KREF
Higher net margin
KREF
KREF
143.0% more per $
KREF
-101.7%
-244.8%
AQST
Faster 2-yr revenue CAGR
AQST
AQST
Annualised
AQST
3.9%
-18.8%
KREF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AQST
AQST
KREF
KREF
Revenue
$13.0M
$25.8M
Net Profit
$-31.9M
$-26.2M
Gross Margin
55.2%
Operating Margin
-221.6%
-105.1%
Net Margin
-244.8%
-101.7%
Revenue YoY
9.7%
-26.6%
Net Profit YoY
-86.8%
-229.6%
EPS (diluted)
$-0.26
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AQST
AQST
KREF
KREF
Q4 25
$13.0M
$25.8M
Q3 25
$12.8M
$25.3M
Q2 25
$10.0M
$30.2M
Q1 25
$8.7M
$31.3M
Q4 24
$11.9M
$35.1M
Q3 24
$13.5M
$37.0M
Q2 24
$20.1M
$40.4M
Q1 24
$12.1M
$39.1M
Net Profit
AQST
AQST
KREF
KREF
Q4 25
$-31.9M
$-26.2M
Q3 25
$-15.4M
$13.8M
Q2 25
$-13.5M
$-29.7M
Q1 25
$-22.9M
$-4.9M
Q4 24
$-17.1M
$20.3M
Q3 24
$-11.5M
$-7.4M
Q2 24
$-2.7M
$25.8M
Q1 24
$-12.8M
$-3.1M
Gross Margin
AQST
AQST
KREF
KREF
Q4 25
55.2%
Q3 25
64.8%
Q2 25
54.4%
Q1 25
58.1%
Q4 24
61.9%
Q3 24
67.2%
Q2 24
77.5%
Q1 24
63.6%
Operating Margin
AQST
AQST
KREF
KREF
Q4 25
-221.6%
-105.1%
Q3 25
-89.6%
50.4%
Q2 25
-113.6%
-101.3%
Q1 25
-222.1%
-18.3%
Q4 24
-114.4%
55.8%
Q3 24
-61.2%
-19.6%
Q2 24
0.3%
63.3%
Q1 24
-74.3%
-8.7%
Net Margin
AQST
AQST
KREF
KREF
Q4 25
-244.8%
-101.7%
Q3 25
-120.6%
54.4%
Q2 25
-135.4%
-98.5%
Q1 25
-263.0%
-15.5%
Q4 24
-143.7%
57.7%
Q3 24
-85.0%
-20.0%
Q2 24
-13.7%
63.9%
Q1 24
-106.4%
-7.9%
EPS (diluted)
AQST
AQST
KREF
KREF
Q4 25
$-0.26
$-0.49
Q3 25
$-0.14
$0.12
Q2 25
$-0.14
$-0.53
Q1 25
$-0.24
$-0.15
Q4 24
$-0.18
$0.22
Q3 24
$-0.13
$-0.19
Q2 24
$-0.03
$0.29
Q1 24
$-0.17
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AQST
AQST
KREF
KREF
Cash + ST InvestmentsLiquidity on hand
$84.6M
Total DebtLower is stronger
$27.5M
Stockholders' EquityBook value
$-33.7M
$1.2B
Total Assets
$160.4M
$6.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AQST
AQST
KREF
KREF
Q4 25
$84.6M
Q3 25
$129.1M
$204.1M
Q2 25
$60.5M
$107.7M
Q1 25
$68.7M
$106.4M
Q4 24
$71.5M
$104.9M
Q3 24
$77.9M
$108.8M
Q2 24
$89.9M
$107.2M
Q1 24
$95.2M
$106.5M
Total Debt
AQST
AQST
KREF
KREF
Q4 25
$27.5M
Q3 25
$45.0M
Q2 25
$45.0M
Q1 25
$45.0M
Q4 24
$32.5M
Q3 24
$45.0M
Q2 24
$45.0M
Q1 24
$45.0M
Stockholders' Equity
AQST
AQST
KREF
KREF
Q4 25
$-33.7M
$1.2B
Q3 25
$-4.1M
$1.2B
Q2 25
$-72.6M
$1.2B
Q1 25
$-60.9M
$1.3B
Q4 24
$-60.2M
$1.3B
Q3 24
$-45.4M
$1.4B
Q2 24
$-35.5M
$1.4B
Q1 24
$-36.3M
$1.4B
Total Assets
AQST
AQST
KREF
KREF
Q4 25
$160.4M
$6.5B
Q3 25
$163.6M
$6.5B
Q2 25
$93.7M
$6.8B
Q1 25
$102.2M
$6.6B
Q4 24
$101.4M
$6.4B
Q3 24
$110.0M
$6.8B
Q2 24
$117.6M
$7.1B
Q1 24
$129.5M
$7.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AQST
AQST
KREF
KREF
Operating Cash FlowLast quarter
$-8.5M
$72.3M
Free Cash FlowOCF − Capex
$-8.6M
FCF MarginFCF / Revenue
-65.7%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-53.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AQST
AQST
KREF
KREF
Q4 25
$-8.5M
$72.3M
Q3 25
$-12.6M
$18.5M
Q2 25
$-7.9M
$21.1M
Q1 25
$-23.4M
$15.9M
Q4 24
$-6.5M
$132.6M
Q3 24
$-11.9M
$49.1M
Q2 24
$-7.0M
$30.6M
Q1 24
$-10.4M
$34.5M
Free Cash Flow
AQST
AQST
KREF
KREF
Q4 25
$-8.6M
Q3 25
$-12.9M
Q2 25
$-8.0M
Q1 25
$-23.5M
Q4 24
$-6.5M
Q3 24
$-12.0M
Q2 24
$-7.0M
Q1 24
$-10.4M
FCF Margin
AQST
AQST
KREF
KREF
Q4 25
-65.7%
Q3 25
-100.6%
Q2 25
-80.2%
Q1 25
-269.9%
Q4 24
-54.8%
Q3 24
-88.3%
Q2 24
-35.0%
Q1 24
-86.4%
Capex Intensity
AQST
AQST
KREF
KREF
Q4 25
0.7%
Q3 25
1.8%
Q2 25
1.1%
Q1 25
1.5%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
0.2%
Cash Conversion
AQST
AQST
KREF
KREF
Q4 25
Q3 25
1.34×
Q2 25
Q1 25
Q4 24
6.54×
Q3 24
Q2 24
1.19×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons